The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 16, 2013
Filed:
Jul. 03, 2008
Edward A. Dennis, La Jolla, CA (US);
Daren Stephens, Morrisville, NC (US);
Samuel David, Dorval, CA;
Ruben Lopez-vales, Catalonia, ES;
Athena Kalyvas, Laval, CA;
George Kokotos, Athens, GR;
Violetta Constantinou-kokotou, Athens, GR;
Efrosini Barbayianni, Athens, GR;
Victoria Magrioti, Athens, GR;
Edward A. Dennis, La Jolla, CA (US);
Daren Stephens, Morrisville, NC (US);
Samuel David, Dorval, CA;
Ruben Lopez-Vales, Catalonia, ES;
Athena Kalyvas, Laval, CA;
George Kokotos, Athens, GR;
Violetta Constantinou-Kokotou, Athens, GR;
Efrosini Barbayianni, Athens, GR;
Victoria Magrioti, Athens, GR;
The Regents of the University of California, Oakland, CA (US);
Abstract
Phospholipase A(PLA) forms are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLAinhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA(cPLA) and/or Group VIA calcium independent PLA(iPLA) and/or Group V secreted PLA(sPLA). Pharmaceutical compositions of compounds having cPLAinhibitory activity (but not iPLAor sPLAinhibitory activity) are useful in treating multiple sclerosis, while compositions of compounds having sPLAinhibitory activity (as well as iPLAand CPLAactivity) are useful in treating spinal cord injuries (with related functional recovery).